September 2024
M	T	W	T	F	S	S
	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30

Insight

Jarushka Naidoo: Intracranial activity of Tarlatamab in 2L SCLC in Ph I DeLLphi-300 Trial

photo taken from Jarushka Naidoo/X

Sep 4, 2024, 06:47

Jarushka Naidoo: Intracranial activity of Tarlatamab in 2L SCLC in Ph I DeLLphi-300 Trial

Jarushka Naidoo shared on X:

“Intracranial activity of Tarlatamab in 2L SCLC in Ph I DeLLphi-300 Trial:

– 152 patients, mfollow
-up 12.1m
– intracranial ORR 62.5% (all prior RT)
– mOS 17.5m, ORR 25%

Important data, now to make this easier to give to patients.”

Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update

Authors: Afshin Dowlati, Horst-Dieter Hummel, Stephane Champiat, Maria Eugenia Olmedo, Michael Boyer, Kai He, Neeltje Steeghs, Hiroki Izumi, Melissa L. Johnson, Tatsuya Yoshida, Hasna Bouchaab, Hossein Borghaei, Enriqueta Felip, Philipp J. Jost, Shirish Gadgeel, Xi Chen, Youfei Yu, Pablo Martinez, Amanda Parkes, Luis Paz-Ares,

Jarushka Naidoo

Source: Jarushka Naidoo

For more posts by Jarushka Naidoo, visit oncodaily.com

Dr. Jarushka Naidoo is a thoracic oncologist at the Beaumont Hospital Dublin (Ireland), Professor in RCSI and Adjunct Professor of Oncology at Johns Hopkins University. She currently serves as national lung cancer lead for Cancer Trials Ireland. She serves on several international guideline panels including ASCO and SITC (Society of Immunotherapy for Cancer), and is an experienced clinical trialist- having developed and completed several investigator-initiated, industry-funded and cooperative group clinical trials.

She has received a number of grants including a young investigator award from the International Association for the Study of Lung Cancer (IASLC), Lung Cancer Foundation of America (LCFA), and a career development award from the National Institutes of Health (NIH) KL2-program. She is the IASLC Communications Committee Chair.